现在的位置: 首页 > 综合 > 正文

微软与默克签署协议收购 Rosetta Biosoftware 资产,巩固在生命科学行业内的地位

2013年01月25日 ⁄ 综合 ⁄ 共 4745字 ⁄ 字号 评论关闭

美通社-PR Newswire华盛顿州雷蒙德6月1日电 微软公司 (Microsoft Corp.) 今天宣布,该公司已就收购 Rosetta Inpharmatics LLC 旗下业务单位 Rosetta Biosoftware 的某些资产与默克公司 (Merck & Co., Inc) 达成了一项协议。Rosetta Inpharmatics LLC 是默克公司旗下全资子公司。这项交易让微软能够把遗传学、基因组学、代谢物组学和蛋白质组学数据管理软件整合进微软 Amalga Life Sciences 平台,以增强翻译研究能力。此外,为了充实 Amalga Life Sciences 平台以满足新兴制药研究的需求,微软还将与默克建立战略合作关系。

  根据协议,默克将成为微软 Amalga Life Sciences 2009 平台的一家客户,并将就结合了 Rosetta Biosoftware 技术的新解决方案的趋势和演化向微软提供战略投入。该软件平台将帮助推动默克改善原本已经十分先进的研究能力。

  Merck Research Laboratories 副总裁 Rupert Vessey 表示:“这项协议为 Rosetta Biosoftware 技术建立了稳定的可持续平台。除此以外,我们期待与微软协作开发新的生物信息解决方案,从而实现并加快药物的发现与开发。这正是我们先前宣布的旨在改善我们基本研究工作的效率以确保长期的产品线生产力的战略的一部分。”

  微软医疗解决方案集团公司副总裁 Peter Neupert 则表示:“我们为与默克的协作并通过互补性的 Rosetta Biosoftware 的资产来增强 Amalga Life Sciences 的能力而感到振奋。整合而成的新产品将让客户能够改善基因组学、生物学和研究数据的管理与分析,帮助更快地把能够挽救生命的药物和疗法推向市场,并且加速个体化用药的实现。”

 

 

 

Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Science

REDMOND, Wash. - Microsoft Corp. today announced that it has signed an agreement with Merck & Co. Inc. to acquire certain assets of Rosetta Biosoftware, a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co. Inc. The deal allows Microsoft to incorporate genetic, genomic, metabolomic and proteomics data management software into the Microsoft Amalga Life Sciences platform for enhanced translational research capabilities. In addition, Microsoft will establish a strategic relationship with Merck to enhance the Amalga Life Sciences platform to meet emerging pharmaceutical research needs.

Under the terms of the agreement, Merck will become a customer of the Microsoft Amalga Life Sciences 2009 platform and also will provide strategic input to Microsoft on the direction and evolution of new solutions incorporating Rosetta Biosoftware technologies. The software platform will help drive improvements in Merck’s already advanced research capabilities.

“This agreement establishes a stable and sustainable platform for the Rosetta Biosoftware technology. In addition, we look forward to collaborating with Microsoft to develop new bioinformatic solutions to enable and expedite drug discovery and development,” said Rupert Vessey, vice president, Merck Research Laboratories. “This is part of our previously announced strategy designed to improve the effectiveness and efficiency of our Basic Research operations to ensure long-term pipeline productivity.”

“We’re excited to collaborate with Merck and augment the capabilities of Amalga Life Sciences with the complementary assets of Rosetta Biosoftware,” said Peter Neupert, corporate vice president, Health Solutions Group, Microsoft. “The newly combined offering will enable customers to improve the management and analysis of genomic, biological and research data, helping to bring lifesaving drugs and therapies to market faster and accelerate the realization of personalized medicine.”

Introduced in April 2009, Microsoft Amalga Life Sciences is a new software platform designed to transform health and life sciences research data into the critical knowledge needed for the discovery of new treatments. The platform helps organizations across the life sciences spectrum accelerate research and discovery efforts by automating the management and analysis of massive, heterogeneous research data. This gives scientists and researchers the opportunity to redesign, manage and control research processes to increase productivity, reduce errors and improve decision-making.

The deal is expected to close at the end of June 2009, and the new Amalga Life Sciences platform incorporating Rosetta Biosoftware technologies is slated to be available in early 2010. Microsoft is pursuing hiring Rosetta Biosoftware employees who can fill roles that are critical to the effective incorporation of Rosetta Biosoftware technologies into the Amalga Life Sciences platform. Until the deal is closed, Rosetta Biosoftware will continue to operate as a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck.

About Microsoft in Health

Microsoft is committed to improving health around the world through software innovation. Over the past 12 years Microsoft has steadily increased its investments in health, with a focus on addressing the challenges of health providers, health and social services organizations, payers, consumers, and life sciences companies worldwide. Microsoft closely collaborates with a broad ecosystem of partners and develops its own powerful health solutions, such as Amalga and HealthVault. Together, Microsoft and its industry partners are working to advance a vision of unifying health information and making it more readily available, ensuring the best quality of life and affordable care for everyone.

About Microsoft

Founded in 1975, Microsoft (Nasdaq “MSFT”) is the worldwide leader in software, services and solutions that help people and businesses realize their full potential.

Note to editors: If you are interested in viewing additional information on Microsoft, please visit the Microsoft Web page at http://www.microsoft.com/presspass on Microsoft’s corporate information pages. Web links, telephone numbers and titles were correct at time of publication, but may since have changed. For additional assistance, journalists and analysts may contact Microsoft’s Rapid Response Team or other appropriate contacts listed at http://www.microsoft.com/presspass/contactpr.mspx.

抱歉!评论已关闭.